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Osteosarcoma (OS) is the most common type of bone cancer in children
and adolescents. With the current treatment approaches, the survival rate is
60-70%. Therapies for treating OS have remained the same over the past thirty
years. There is a need for developing more effective therapies, which can
significantly improve the survival of the patients who do not respond well to
current therapeutic strategies. Epidemiological evidence indicates impaired
regulation of cell proliferation and survival appears to be a key event in the
etiology of the disease. Previous in vitro and in vivo studies suggest that
1α,25-dihydroxyvitamin D3 (calcitriol or 1,25D) has significant antineoplastic
activity by inhibiting cell proliferation and inducing differentiation and apoptosis in
breast, prostate, colon, skin, and brain cancer. The molecular mechanisms for
calcitriol-mediated cancer prevention are still unknown. In particular, the role of
calcitriol in modulating OS needs to be investigated.
The primary objective of the study was to find out the relationship between
calcitriol treatment and expression levels of vitamin D target genes: vitamin D
receptor (VDR), 1α-hydroxylase (CYP27B1), 24 hydroxylase (CYP24A1), runt 
related transcription factor-2 (RUNX-2), and osteocalcin (OCN), by evaluating and
comparing the transcription and translation levels of the genes in response to
calcitriol at 3 days, 9 days, as well as 15 days (for gene expression) and 21 days
iv
(for protein translation) of cellular growth in OS cell line (143B). The second
objective was to rule out the possibility of serum components in masking of any
antiproliferative effects of calcitriol by comparing proliferation patterns of OS cell
lines cultured in high serum (10%) vs. low serum (1%) and very low serum (0.1%)
concentrations in OS 143B, SaOS-2, and U2OS cell lines.
Our preliminary results from this pilot study suggest calcitriol has no
significant effect on expression of vitamin D target genes (VDR, CYP27B1,
CYP24A1, RUNX-2 and OCN) in 143B OS cell at the mRNA and protein levels,
and exerts no significant anti-proliferative effect in serum-reduced medium in
143B, SaOS-2, and U2OS OS cell lines.
v
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Osteosarcoma (OS) is the most common type of bone cancer in children
and adolescents (1). Current treatments of OS are surgery and chemotherapy.
For many patients, a combination of these two treatments successfully controls
the tumor. To some patients with impossible complete surgical excision and poor
response to chemotherapy, a high risk of relapse and recurrence exists. Impaired
regulation of cell proliferation and differentiation appears to be a key event in the
etiology of the disease. Novel therapeutic regimens targeting inhibition of cell
proliferation and induction of differentiation in OS are needed.
Preclinical research studies indicate calcitriol (1α,25(OH)2D3) exhibit
potential anticancer properties due to anti-proliferative effects, activating apoptotic
pathways and inhibiting angiogenesis (2). Calcitriol potentiates the anticancer
effects of many cytotoxic and anti-proliferative anti-cancer agents. One possible
anti-proliferative mechanism of calcitriol in OS cells is binding to a nuclear vitamin
D receptor (VDR), which acts as a transcription factor and modulates the
expression of genes involved in cell cycle progression (3, 34-38), differentiation
(4), angiogenesis (2, 6), and apoptosis (6, 40-44).
Calcitriol induces differentiation in numerous types of benign and malignant
cells (4). Activation of transcription factors by calcitriol increases expression of
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multiple genes involved in differentiation. Emerging evidence suggests
osteosarcoma should be considered as a differentiation disease with defects in
osteoblast differentiation from mesenchymal stem cells (MSC) (5). Therapies of
promoting differentiation in OS cells can be an effective treatment strategy against
OS.
Calcitriol modulates the expression of pro- (Bax, Bak and Bad) and
anti-apoptotic (Bcl-2) in breast, colon, prostate, myeloma, and lymphocytic
leukemia cells (6).
In vitro and in vivo studies clearly demonstrate that clacitriol modulates
proliferation, differentiation and apoptosis of tumor cells. The mechanisms
underlying the antineoplastic effects of calcitriol remain to be determined.
Statement of Purpose
Previous studies in Dr. Garimella’s lab demonstrated that both 25(OH)D3
and calcitriol can stimulate differentiation and apoptosis, however, neither one has
any significant effect on proliferation of two OS cell lines, 143B and SaOS-2. The
exact mechanism(s) underlying calcitriol induced differentiation and apoptosis is
(are) not clear.
In order to find out the role of vitamin D in OS cells in proliferative and
differentiative stages and the transition between these two stages, the present
study investigated vitamin D target genes (including VDR, CYP27B1, CYP24A1,
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RUNX-2, and osteocalcin-OCN) by comparing the expression of these genes in
response to calcitriol during proliferation, post-proliferation, and differentiation of
OS cell lines, 143B versus control osteoblast (Ob, MC3T3-E1-mouse
pre-osteoblast cell line).
To rule out the possibility of activity of vitamin D binding serum proteins that
may play a role in suppressing or masking the antiproliferative potential of vitamin
D against osteosarcoma, we compared the proliferation patterns of OS cell lines
in high serum vs. low serum growth conditions.
In this project, the osteosarcoma cell line, 143B, was evaluated for vitamin D
target gene (VDR, CYP27B1, CYP24A1, RUNX-2 and OCN) in response to
calcitriol treatment. The 143B cell line has high metastatic potential and harbors a
mutation in Ras gene. Activation of Ras gene in commonly seen in colon cancer
and pancreatic cancer. Clinical significance of occurrence of Ras activation in OS
is not clear. Not many studies have been done in 143B cell line until now. This
osteosarcoma cell line is of interest to study.
Study Objective
The primary objective of this study is to find out the relationship between
calcitriol treatment and expression levels of vitamin D target genes by evaluating
and comparing the expression and translation levels of the genes in response to
calcitriol at 3 days (defined as proliferation stage), 9 days (defined as
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post-proliferation stage), 15 days (defined as differentiation stage for gene
expression), and 21 days (defined as differentiation stage for protein translation)
of cellular growth in OS cell line (143B).
The secondary objective of this study was to rule out the possibility of
serum components in masking of any antiproliferative effects of calcitriol by
comparing proliferation patterns of OS cell lines cultured in high serum (10%) vs.





Osteosarcoma is a malignant bone tumor predominant among children and
adolescents. About 400-600 cases of OS are reported annually. Using the current
treatment options, the patients with osteosarcoma have a 60-70% survival rate.
The disease is severe in the remaining one third of the population who does not
respond well to chemotherapy and often succumb to pulmonary metastasis.
There is a need to identify novel therapeutic regimens against osteosarcoma.
Figure 1 Vitamin D Metabolism. In response to UV light, 7-dehydrocholestrol and
pre-vitamin D3 convert to vitamin D3. Vitamin D3 transforms to 25-hydroxyvitamin D3 in the
liver by 25-hydroxylase. In the kidney, 25-hydroxyvitamin D3 undergoes a hydroxylation
reaction in the presence of 1α-hydroxylase to form 1,25-dihydroxyvitamin D3. Calcitriol is
catabolized by 24-hydroxylase to calcitroic acid.
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Vitamin D is a secosteroid hormone historically known for its role in
maintaining bone health by regulating calcium and phosphate homeostasis. The
chemical structures of vitamin Ds were first specified in the 1930s (64). The
classic bone disease resulting from a deficiency in vitamin D is called rickets in
children and osteomalacia in adults. Vitamin D comes in many forms. The two
most important isomers are vitamin D2 and vitamin D3. Vitamin D2 comes from
yeasts and plants while vitamin D3 is rich in fatty fish and fatty fish oil. Vitamin D
can be obtained from fortified foods such as milk and milk products. It also can be
synthesized in skin in the presence of UV light (Figure 1). Exposure of the skin to
the UV rays of sunlight induces the conversion of 7-dehydrocholesterol to
previtamin D3. Then previtamin D3 undergoes a thermal isomerization to vitamin
D3. Vitamin D3 is transported to the liver where it is converted to
25-hydroxyvitamin D3 or 25(OH)D3, the major circulating metabolite of vitamin D3
in the body. The final activation in the kidney is catalyzed by 1α-hydroxylase 
(1α-OHase) forming calcitriol (1α,25(OH)2D3), the active form of the vitamin.
Catabolic inactivation is carried out by 24-hydroxylase (24-OHase).
Calcitriol, the biologically active form of vitamin D, is historically known for its
role in regulating calcium and phosphorus homeostasis. Epidemiological studies
point to a relationship between vitamin D deficiency and cancer risk. The role of
calcitriol in the control and regulation of cellular growth and differentiation is
emerging in various cell types, including carcinomas of the breast, prostate, colon,
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skin, and brain, myeloid leukemia cells, and others (11,12), and of significant
interest to cancer researchers.
Calcitriol has significant antineoplastic activity in numerous in vivo and in
vitro studies suggesting the hypothesis of several mechanisms involving in the
control of the activity. The mechanisms underlying the antineoplastic roles of
1α,25(OH)2D3 are not clear and they may vary with different tumor models and
experimental conditions. Calcitriol executes its anticancer effect by inhibiting
proliferation associated with cell cycle arrest (3, 34-38), inducing differentiation (4)
and apoptosis (6, 40-44) and by reducing invasiveness as well as angiogenesis (2,
6).
Figure 2 Genomic and non-genomic pathways of calcitriol mode of action. In the genomic
pathway, calcitriol binds to the VDR and recruits retinoic X receptor (RXR) to form a
complex which interacts with vitamin D response elements (VDRE) to regulate gene
transcriptions. In non-genomic pathway, calcitriol binds to plasma membrane VDR to
execute rapid effects. (Source: Rama Garimella)
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Calcitriol exerts its antineoplastic activity through both genomic and
non-genomic pathways (Figure 2). The genomic pathway is mediated by the
binding of calcitriol to VDR. This binding activates VDR to recruit cofactors,
including retinoic acid X receptor (RXR), to form a complex to bind to vitamin D
response elements (VDRE) located in the promoter region of target genes and
regulate gene transcriptions (13). VDR is a member of the steroid hormone
receptor superfamily and is present in many tissues, including intestine, kidney,
bone, brain, stomach, heart, pancreas, skin, activated T and B lymphocytes, colon,
ovary, breast, and prostate (14,15). It regulates gene expression in a
ligand-dependent manner (16). Multiple genes contain VDRE in their promoter
region, including bone-related genes (6). These findings suggest that vitamin D
play a role in controlling cellular growth in the non-neoplastic normal tissues.
However, VDR is not the only factor responsible for the efficacy of calcitriol in
controlling tumor growth. In prostate cancer cells, altered expression of the steroid
receptor corepressor SMRT or defective VDR localization determined the
resistance to antiproliferative effects of calcitriol (17).
Nongenomic actions of calcitriol are rapid and do not depend on
transcription directly. This pathway begins at the plasma membrane and involves
a non-classical membrane receptor (18) and a
1α,25(OH)2D3-membrane-associated rapid-response steroid binding protein
(1α,25D3-MARRS) (19). Nongenomic effects of calcitriol can activate the
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Raf-mitogen-activated protein kinase extracellular signal-regulated kinase kinase
(MEK)-mitogen-activated protein kinase (MAPK)-extracellular signal-regulated
kinase (ERK) cascade in skeletal muscle cells (20), which subsequently increases
the transcriptional activity of the VDR and stabilizes the receptor, thereby
cooperates with the classical genomic pathway to activate VDR and lead to the
antiproliferative effects of calcitriol.
Abe et al. for the first time reported that calcitriol stimulates terminal
differentiation in mouse myeloid leukemia cells, thereby suggesting an
antineoplastic role for vitamin D against myeloid leukemia (21). Since then many
in vivo and in vitro studies have demonstrated the anticancer effects of calcitriol in
the cancer of bladder (22), breast (23), colon (24), endometrium (25), kidney (26),
lung (27), pancreas (28), prostate (29), osteosarcoma (30), neuroblastoma (31),
glioma (32), melanoma (33), and others. The anticancer effect of calcitriol is
mainly through the enhancement or suppression of the transcription of key genes
by the ligand-activated VDR. Indirectly, vitamin D also can alter cellular growth by
interacting with other important transcriptional factors or cell signaling pathways
affecting on cell cycle progression (34-38), differentiation (4), and apoptosis (6,
40-44).
Calcitriol exerts its antineoplastic effects mainly by antiproliferative actions.
Calcitriol induces arrest in the cell cycle in numerous cell lines (24-38). Cell cycle
consists of 5 phases including gap 0 (G0), gap 1 (G1), synthesis (S), gap 2 (G2),
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and mitosis (M) (Figure 3). The major arrest is at the G0/1 to S phase transition.
Calcitriol activates the transcriptions of cyclin-dependent kinase (CDK) inhibitors
p27Kip1 and p21Waf1 while CDK is important for the transcription of many genes
necessary for DNA replication, mitosis, and control of phase transition during cell
cycle. The activation of CDK inhibitors is responsible for cell cycle arrest (34, 35).
Figure 3 Cell Cycle. Cell cycle consists of 5 phases including gap 0 (G0), gap 1 (G1),
synthesis (S), gap 2 (G2), and mitosis (M).
Besides the CDK inhibitors, mitogenic signals may also be regulated by
calcitriol, including signaling through the mitogenic ERK/mitogen-activated protein
kinase pathway, to inhibit cellular growth (44). In addition, calcitriol elicits













epidermal growth factor receptors (45), transforming growth factor β (46, 47), and 
components of the insulin-like growth factor system (48-50).
Vitamin D compounds may alter cellular proliferation variably in different cell
types. Calcitriol and vitamin D analogues had an antiproliferative effect on the
growth of primary cultures of human prostatic cells (51). In contrast, in normal
mouse epidermis calcitriol induces cell proliferation (53). Concentrations of
calcitriol used in cell culture studies also are critical in modulating effects on
cellular proliferation and differentiation. In primary mouse epidermal keratinocytes,
low concentration (picomolar) of calcitriol stimulates proliferation while high
concentration (nanomolar to micromolar) inhibits proliferation (53). The timing of
induction of antiproliferative effect of calcitriol varies from cell to cell and also
dependent on dose or concentration calcitriol. More research is needed to clarify
the underlying mechanisms of cell- and dose-specification.
Calcitriol induces differentiation in numerous types of benign and malignant
cells (4). Calcitriol induces differentiation by activation of transcription factors
leading to expression of multiple genes involved in differentiation. Work
conducted at Dr. Garimella’s lab had shown higher concentration (≥100 nM) of 
calcitriol increased alkaline phosphatase (ALP) enzyme activity in osteosarcoma
143B cell line suggesting vitamin D may act as a differentiation agent in these
cells.
According to emerging evidence, osteosarcoma is commonly regarded as a
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disease caused by genetic and epigenetic disruptions of osteoblast differentiation
pathways from mesenchymal stem cells (MSC) (5). Osteogenic stimuli failed to
induce differentiation of most OS cells which indicates the possible differentiation
defects exist in OS cells (55). Promoting differentiation in otherwise uncontrolled
rapidly proliferating OS cells is a potential therapy for OS in contrast to current
chemotherapies focus on reducing proliferation of OS tumors.
Induction of apoptosis also plays a key role in anticancer effect by calcitriol
in the breast cancer (39), colon cancer (40), prostate cancer (41), myeloma (44),
and lymphocytic leukemia (42). But vitamin D exerts no effects on induction of
apoptosis in normal astrocytes, melanocytes, and mammary cells (56). In MCF-7
breast cancer cells (39), prostate cancer cells (41) and B-cell chronic lymphocytic
leukemia cells (43), calcitriol down-regulated the anti-apoptotic protein Bcl-2
which is overexpressed in many cancer cells. In some cancer cell lines, calcitriol
also induced up-regulation of the pro-apoptotic protein Bax. The stimulation was
independent on p53. Calcitriol induces apoptosis by tipping the balance of
pro-apoptotic and/or anti-apoptotic proteins toward apoptosis rather than cell
survival (4).
Markers of cellular responsiveness to the antineoplastic action of calcitriol
Antineoplastic effects of calcitriol are variable in different cell types, even the
cells derive from the same tissue. Genes regulating vitamin D metabolism (VDR,
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CYP27B1, and CYP24A1) and osteoblastic differentiation (RUNX-2 and OCN)
genes are regarded as good markers to determine the cellular responsiveness of
OS cell lines to calcitriol treatments.
Vitamin D Receptor (VDR)
There is enough evidence regarding a positive correlation between the
status of VDR and the effects of calcitriol. To some extent, the expression level
and the nuclear localization of the VDR determine the cellular sensitivity to growth
inhibition of calcitriol. Studies in VDR knockout models demonstrated the
significance of calcitriol/VDR interaction and signaling pathways in response to
and execution of the anticancer activity of calcitriol. For example, VDR-null mice
showed hyperproliferation and increased mitotic activity in the descending colon
(56). VDR ablation in mouse increased chemical carcinogenesis in mammary,
epidermis and lymphoid tissues (57).
1α-Hydroxylase (1α -OHase) and 24-Hydroxylase (24-OHase) 
The final activation of calctriol from 25(OH)D3 occurs in the kidney and is
catalyzed by the enzyme 1α–OHase (encoded by gene CYP27B1). The catabolic 
degradation is carried out by the enzyme 24-OHase (encoded by gene CYP24A1).
Calcitriol is tightly controlled by the feedback regulation in the cells to prevent
toxicity of vitamin D. Excess build-up of calcitriol is prevented by the cooperative
14
actions of 1α–OHase and 24-OHase. Thus, expression levels of these two 
enzymes may indicate the metabolism status and/or activity of calcitriol in the
cells.
RUNX-2
RUNX-2 is a member of the runt-related transcription factors and an
essential mediator of the osteoblast phenotype and plays a critical role in the
process of osteoblast differentiation. RUNX-2 has suppressive activity in
osteoblasts and is controlling osteoblast differentiation (65). RUNX-2-null model
demonstrated a cartilaginous skeleton with complete absence of ossification
suggesting the importance of RUNX-2 in chondrogenesis and osteogenesis (53).
In addition, when RUNX-2 is overexpressed in chondrocytes, it causes ectopic
chondrocyte hypertrophy and endochondral ossification, suggesting the
importance of RUNX-2 in controlling differentiation of both chondrocytes and
osteoblasts (5). RUNX-2 is expressed at higher levels in human osteosarcoma
cell line OS1 than in human fetal osteoblasts (65). The expression of RUNX-2
gene is a common and appropriate marker for osteogenic differentiation.
Osteocalcin (OCN)
Osteocalcin (OCN) is a noncollagenous protein found in bone. It is secreted
by osteoblasts and plays an important role in regulating bone mineralization as
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well as calcium homeostasis. Mineralization of extracellular matrix is a
characteristic feature of a differentiated osteoblast. Osteocalcin is often used as a
biochemical marker or biomarker for the bone mineralization process.
Altered expressions and functional activities of proteins of vitamin D target
genes (VDR, CYP27B1, CYP24A1, RUNX-2 and OCN) are observed in many
tumor types (2). There is a need to clarify the expression levels of these markers
in OS cells.
Role of fetal bovine serum (FBS) in modulating calcitriol mediated effects on
cellular proliferation and differentiation
Fetal bovine serum is an undefined reagent to provide growth factors for cell
culture. Most investigators considered the components in FBS would mask or
suppress the antiproliferative effect of calcitriol. Thereby, to reduce the variable
and uncertain factors, multiple studies (58-61) grow cells in serum-reduced
medium or other defined growth factors or use of charcoal-stripped serum.
Calcitriol has biphasic effects on cell growth with/without the presence of a growth
medium containing whole FBS in prostate cancer cells (66). Some prostate
cancer cell lines are inhibited by calcitriol in the presence of 10% FBS, however,
are stimulated in the presence of charcoal-stripped, sulfatase-treated FBS





Experiments were conducted at The University of Kansas Medical Center
(KUMC) in the Bone Research Lab (G002 WHE) and G003 Lied Building and the
department of Dietetics and Nutrition from January, 2009 to April, 2010.
Ethics
This study qualifies for exemption from Human Subjects Approval as the cell
lines used in the proposed study are considered Secondary data. The cells are
publicly available and contain no identification markers.
Materials and Methods
Reagents
Calcitriol was purchased from Enzo Life Sciences International Inc.,
(Plymouth Meeting, PA). Stock solutions were prepared and frozen at -20°C.
Mito+ serum extender were purchased from Thermo Fish Scientific Inc., (Waltham,
MA) and used according to manufacturer’s recommendation.
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Cell Lines
Human osteosarcoma cell lines, 143B (purchased from American Type
Culture Collection, Rockwell, MD) and control osteoblast cells (MC3T3-E1-mouse
pre-osteblast cell line) (provided by Professor Rowe from Kidney Institute,
University of Kansas Medical Center, Kansas City, Kansas) were used in this
study.
Stock Cell Culture
Osteosarcoma cells and osteoblast cells were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) containing 10% and 20% fetal bovine serum
(FBS), respectively, as stock cultures. Cells were maintained by standard
methodology at 37℃ in humidified (95% air : 5% CO2) incubator.
Cell Culture for Experiments
For different experiments, cells were seeded in 6 well plates in DMEM
supplemented with 1% FBS and 0.1% mito+ serum extender. The standard cell
density of 143B and MC3T3 were 0.5 X 104 and per well, respectively. Mito+
serum extender is a concentrated, fully defined formulation of hormones, growth
factors (EGF and FGF), and other metabolites (insulin and steroid hormones).
The use of mito+ serum extender instead of FBS for cell growth is to rule out the
undefined factors (vitamin D binding proteins present in the serum) masking the
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effects of vitamin D.
Proliferation and Post-proliferation Study
Osteosarcoma and osteoblast cells were plated in 6 well plates with the
standard cell density. Ethanol (0.01%) (control) or calcitriol (100 nM) were added
to the cultures 4 h after plating. Medium was changed every two days with fresh
treatments (ethanol control and calcitriol) (Figure 4). Based on previous study in
Dr. Garimella’s lab, the initiation concentration of antineoplastic effects of calcitriol
is 100 nM. In this study, we used 100 nM calcitriol as treatment.
Figure 4 Schedules of Proliferation and Post-Proliferation Studies. Arrows indicate
treatment/processing protocol.
After 72 h (proliferative) or 9 days (post-proliferative), RNA was isolated by
using RNeasy Mini Kit (Qiagen, Santa Clara, CA) and cell-lysates containing
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proteins were prepared by lysing the cells in Triton-lysis buffer. For each
experiment, N equals to or is larger than three.
Figure 5 Schedule of Differentiation Study. Arrows indicate treatment/processing protocol.
Differentiation Study
Osteosarcoma and osteoblast cells were plated in 6 well plates with the
standard cell density. Ethanol (0.01%) (control) or calcitriol (100 nM) were added
to the cultures 3 days after plating. Differentiation-inducing agents, L-ascorbic
acid 2-phosphate and β-glycerophosphate, were added at the concentrations of 
50 μg/ml (67) and 5 nM, respectively. Medium was changed every two days with 
fresh treatments.
After 15 days, RNA was isolated by using RNeasy Mini Kit (Qiagen, Santa
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Clara, CA) while after 21 days, protein was extracted by using Triton-lysis buffer
(Figure 5). For each experiment, N equals to or is larger than three.
Real-time Quantitative Polymerase Chain reaction (qPCR)
RNA was reverse-transcribed by using High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems Inc., Silicon Valley, CA). Complementary
DNA was tested with probing VDR, CYP27B1, CYP24, Runx2 and OCN by
real-time qPCR. All primers were tested and the optimal primer concentrations
were determined at 900 nM. Real-time qPCR was performed using 7500 real time
PCR system (Dr. Jinxi Wang, Department of Orthopedic Surgery, University of
Kansas Medical center) according to the standard protocol as recommended by
Applied Biosystems 7500 sequence Detection system and software (Applied
Biosystems, Foster City, CA). Sequences of all PCR primers are published by
Atkins et al. in 2007(62). Relative expression between samples was calculated
using the comparative cycle threshold (CT) method (△CT) (62). The formula is
XN=2
-△CT . XN is the relative amount of target gene and △CT is the difference
between the CT of the gene and the CT for the GAPDH. The calibrator, MC3T3E1,
was used in this study.
Western Blotting
The expression of VDR, 1α-OHase, 24-OHase, RUNX-2, and OCN proteins 
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were assessed by western blotting analysis. Protein concentration of the crude
cell lysates was determined by Bio-Rad DC protein assay. About 40-60 μg protein 
of crude cell lysate was solubilized in SDS-sample buffer, and electrophoresed on
a 12% denaturing polyacryalmide gel. For western blotting, the proteins from the
gel were transferred on to a polyvinylidene fluoride (PVDF) microporous
membrane and incubated with the primary antibodies: anti-VDR, anti-1α-OHase, 
anti-24-OHase, anti-Runx2, and anti-OCN. The concentration of all primary
antibodies is 200 μg/ml. The working concentration of the above primary 
antibodies used in western blot analysis is 1:200. The primary antibodies were
purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Following
incubation with horse-radish peroxidase (HRP) conjugated secondary antibody,
the immunostained bands were visualized by ECL chemiluminescent detection
system (Amersham Biosciences, Piscataway, NJ). The developed films were
scanned using a desktop scanner (HP ScanJet 4100C) and final images of
western analyses were created using Adobe Photoshop. Breast cancer cell MCF7
cell extract and kidney tissue extract are used as positive control.
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tet
razolium (MTS) Cell Proliferation Assay
Cells were cultured in 96 well plates in DMEM containing 1% and 0.1% FBS.
The standard cell density of 143B cell line was 8000 cells per well. Ethanol
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(0.01%) (control) or calcitriol (10 nM and 100 nM) were added after 4 h and 48 h.
After 96 h, cellular proliferation was assayed by MTS assay.
Analysis of Data
Excel software (Microsoft Corp., Redmond, WA, USA) was used for all
statistical analysis. Means and standard deviations were calculated for all data
measures. T-test and Analysis of Variance (ANOVA) was used to analyze
differences in experimental and control data, and differences between groups. A p
value < 0.05 was considered statistically significant.
Chapter 4
Results
Expression of Vitamin D Target Genes mRNA in Osteosarcoma 143B
Vitamin D target genes (VDR, CYP27B1, CYP24A1, RUNX-2, and OCN)
are expressed in 143B OS cells. No significant differences exist between control
and calcitriol-treated groups in proliferative, post-proliferative, and differentiation
stages. No significant differences of VDR, CYP24A1, RUNX-2, and OCN are
found when comparing control or calcitriol-treated samples in three stages. Only
CYP27B1 mRNA is increased in post-proliferative and differentiation stages when
comparing to proliferative stage. Expression of OCN mRNA is very low comparing
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addition of calcitriol (100 nM) for 3 days, 9 days, and 15 days, and processed for real-time
PCR analysis, for (A) VDR, (B) CYP27B1, (C) CYP24A1, (D) RUNX-2 and OCN mRNA
expression, as described. Data are expressed as mean expression normalized to
GAPDH, ±S.D. of triplicate reactions performed on at least triplicate samples. Significant
difference was determined using Student’s t-test and ANOVA, and is indicated by *(p <
0.05) and # (p < 0.005). (E) Expression changes of VDR, CYP27B1, CYP24A1, RUNX-2,
and OCN in proliferation, post-proliferation and differentiation stages.
Protein Expression of Vitamin D Target Genes in Osteosarcoma 143B
Vitamin D target genes (VDR, CYP27B1, CYP24A1, RUNX-2, and OCN)
are translated to protein at a detectable amount in 143B OS cells according to the
results of western blot. The expected molecular weight of VDR is 55 kDa, of
1α-OHase is 56 kDa, of 24-OHase is 59 kDa, of RUNX-2 is 57 kDa, and of OCN is 
55 kDa. All the proteins were detected at 75 kDa which are higher than their
expected molecular weights. Presence of higher molecular weight forms of the
above proteins in 143B cell lines might be due to post-translational modifications.
Breast cancer cell line MCF-7 (Lane 1, Fig. 7A) cell lysate, and kidney (Lane 7,
Fig. 7B, 7C,7E) tissue lysate were used as standards for VDR, 1α-OHase, and 
24-OHase expression respectively. Expression of 1α-OHase in all the experiment 
samples was detected as 75 kDa band. In addition to the 75 kDa band, a 55 kDa













Figure 7. Effect of calcitriol on vitamin D target genes protein expressions. 143B was
cultured in serum-reduced medium (supplemented with mito+ serum extender), with or
without the addition of calcitriol (100 nM) for 3 days, 9 days, and 21 days, and processed
for western blot anaylsis, for (A) VDR, (B) CYP27B1, (C) CYP24A1, (D) RUNX-2 and (E)
OCN protein expression, as described.
Serum Masking Effects on Anti-Proliferation Activity of Calcitriol
In the cell proliferation MTS assay, cells were grown in serum-reduced
75K
75K
(supplemented with mito+ serum extender) medium for 4 days. Calcitriol has no
significant effect on cell proliferation in all three osteosarcoma cell lines, SaOS-2,
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Figure 8. MTS cell proliferation assay. Cells were cultured in serum-reduced medium (1%
or 0.1 % FBS), with or without the addition of calcitriol at two concentration (10 nM and




In this study, we confirmed osteosarcoma cell line, 143B, contained the
vitamin D regulatory system (VDR, CYP27B1, CYP24A1) and vitamin D
responsive target genes and their encoded proteins (RUNX-2 and OCN) by
real-time qPCR and western blotting studies. To our best knowledge, this is the
first report of expression of vitamin D target genes (VDR, CYP27B1, CYP24A1,
RUNX-2 and OCN) in the osteosarcoma 143B cell line.
The mRNAs of VDR, CYP27B1, and CYP24A1 are expressed by 143B cells
in all three stages (Fig. 6A, 6B, 6C). No significant differences existed between
control and calcitriol-treated groups in three stages. No significant effect was seen
in a time-dependent manner except CYP27B1. CYP27B1 mRNA was significantly
increased with time. Differences were significant between proliferation versus
post-proliferation, proliferation versus differentiation groups, but not between
post-proliferation versus differentiation when comparing control to control and
calcitriol-treated to calcitriol-treated samples.
In proliferative and post-proliferative stages, there is a trend of increased
expression of VDR in calcitriol-treated samples compared to controls. It is not
significant. We can not see any trend of expression changes of CYP27B1 and
CYP24A1 in all three stages.
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Proteins of VDR, CYP27B1, and CYP24A1 were expressed in all three
stages in 143B OS cell (Fig. 7A, 7B, 7C). It was consistent with the results of
real-time qPCR. MCF-7 and kidney tissue lysate were used as a positive control
for the proteins of VDR, 1α-OHase, 24-OHase, RUNX-2, and OCN respectively. 
MCF-7 had a band of VDR at 55 kDa which was the same as the expected
molecular weight. However, in 143B cells, molecular weight of VDR was about 75
kDa. In the 143B cell and kidney tissue lysate, the proteins of 1α-OHase, 
24-OHase, RUNX-2, and OCN were all at the 75 kDa band position. They were all
higher than the expected molecular weights. The presence of the higher
molecular weight forms might due to various post-translational modifications of
protein occurring in different cancer cell types. In the human kidney and renal
clear cell cancer (68), VDR is found at 60 kDa. In human sebocytes (69), VDR is
demonstrated as a band at 53 kDa.
Protein amounts of VDR, 24-OHase, RUNX-2, and OCN in differentiation
samples were higher than samples of the other two stages. Real-time qPCR
results also indicated the greatest amount of mRNA expressions of these genes in
differentiation. In post-proliferative stage, the protein expressions of VDR,
24-OHase, RUNX-2, and OCN were lower than those during proliferation stage.
According to realtime qPCR results, VDR and CYP24A1 mRNA expressions were
not significantly different between proliferation and post-proliferation. The
potential reason for it might be: 1) the lower translation level of VDR and
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CYP24A1 in post-proliferation, 2) the less amount of protein loading to the gel.
Based on the western blotting result of 1-alpha-OHase, we cannot see significant
difference of protein in three stages. That meaned the protein amounts of each
sample were the same. But it is still interesting for future studies.
RUNX-2 and OCN mRNA expressions were lower than the other vitamin D
target genes in differentiation stage in 143B cells. It was possible that RUNX-2
and OCN mRNA were relatively unstable or they get rapidly translated to proteins
(65). No significant differences existed between control and calcitriol-treated
groups. According to western blotting results, RUNX-2 and OCN were expressed
from 3 days with a detectable amount. Previous studies reported OCN expression
in OS cell lines and osteoblast was highly variable. Ryhanen et al. (70) observed
that OCN expression in MG-63 OS cells peaks within 24h of treatment with
vitamin D analogue CB1093. Dass et al. (71) found no OCN expression in
SaOS-2 and 143B cells in cultures, but could detect in tumor lesions induced by
transplanted OS cells in immunodeficient mice. According to previous study in Dr.
Garimella’s lab, expression of osteogenic markers like alkaline phosphatase
enzyme activity was seen by day 15 treated by calcitriol. More studies are needed
to specify the results.
Our study indicates that calcitriol has no significant effects on gene
expressions of vitamin D target genes (VDR, CYP27B1, CYP24A1, RUNX-2 and
OCN) in all three cell growth stages in 143B cell line. A number of studies reported
35
the feedback regulation mechanism of vitamin D. In this study, CYP27B1 and
CYP24A1 mRNA levels did not change between the control and calcitriol-treated
groups. This result contradicted the general explanation of regulatory system of
vitamin D. The inconsistent changes of CYP27B1 mRNA were also reported in
primary human osteoblast NHBC cells (62) and kidney (63). According to the real
time qPCR results in this study, CYP24A1 mRNA expressions were not consistent
in 6 sets of samples (Data not shown). A huge error bar existed among them.
Significant changes between control and calcitriol-treated groups existed in three
groups, but not in the other three groups. More studies and samples are needed
to specify the expression levels of CYP24A1 mRNA. In other cancers, CYP24A1
is regarded as a highly responsive vitamin D target gene. Another point that can
be considered for future experiments is the timing of expression of vitamin D
target genes.
.
Cell Proliferation MTS Assay
In this MTS assay, cells were grown in serum-reduced medium for 96 h.
Calcitriol had no significant effect on cell proliferation in all three OS cell lines,
SaOS-2, 143B and U2OS. In prostate cancer cells (66), calcitriol had biphasic
effects on cell proliferation in the presence/absence of FBS. The results of MTS
assay contradicted the anti-proliferative activity of calcitriol in breast, prostate,
colon, skin, and brain cancer cells (11, 12). The difference was we used a
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serum-reduced medium (1% serum and 0.1% serum) instead of serum-free
medium. Even the medium contained a very low concentration of FBS, the factors
present in FBS may interact with calcitriol and mask its antiproliferative effects.
The reason for the lack of antiproliferative effect in our study might be due to an
early termination (96 h). It was not long enough for calcitriol to exert its inhibitory
effect on OS cells. Our results were consistent with recent studies by Peik et al.
(72) clearly showing that calcitriol did not alter cell proliferation, but induced cell
cycle changes in human mesenchymal stem cells.
Conclusion
Although many studies reported the anti-tumor activity of calcitriol in many
cancer cell types (22-33), we did not find any significant effect of calcitriol on gene
or protein expression of vitamin D target genes (VDR, CYP27B1, CYP24A1,
RUNX-2, and OCN) in 143B OS cell.
Summary
Based on previous research on the anti-cancer effect of calcitriol in other
tumor cells (22-33), we hypothesized calcitriol also has the effect in 143B OS cell
and regulates the transcription and translation levels of vitamin D target genes
(VDR, CYP27B1, CYP24A1, RUNX-2 and OCN). So we conducted this research
to study the regulation exerted by calcitriol in vitamin D target genes by realtime
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qPCR and western blotting. But no significant effect was found. Calcitriol did not
exhibit the anti-cancer effect in 143B OS cell at 100 nM.
Limitation and Suggestion for Future Research
To our best knowledge, this is the first research to indicate expression of
vitamin D target genes (VDR, CYP27B1, CYP24A1, RUNX-2 and OCN) in 143B
OS cell. More studies are needed to validate the results and specify the
underlying mechanisms in 143B OS cell.
This study is an in vitro study. It may overlook the complexity of in vivo tumor
environment. The results need to be validated in animal models.
In this study, some real-time qPCR data had a huge error bar. But due to
limit time, I can not include more samples to improve the results. It might be a
sample error. Also, in the western blotting, as the protein amounts of each sample
are not enough, thus we used stripping buffer to strip the antibody off and then
probed with another antibody. In the Figure 7, we can see the protein bands of
VDR, CYP24A1, RUNX-2, and OCN are almost the same. In order to confirm the
former antibody was gone, after each stripping we used detection reagent to
develop films for 5 min. Thus, it can verify that the bands are target proteins. For
future studies, the western blotting should develop the membrane without
stripping to specify the target proteins.
In all, this is a pilot study of study in expression level of genes in 143B OS
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